Page last updated: 2024-12-08

cgp 6809

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID163402
SCHEMBL ID11226054
MeSH IDM0109655

Synonyms (10)

Synonym
cgp 6809
84069-38-5
3-[(2r)-2-[(2r,3r,4r,5s)-5-ethoxy-4-hydroxy-3-methoxyoxolan-2-yl]-2-methoxyethyl]-1-methyl-1-nitrosourea
cgp-6809
ethyl-6-deoxy-3,5-di-o-methyl-6-(3-methyl-3-nitrosoureido)glucofuranoside
SCHEMBL11226054
DTXSID701004355
ethyl 6-deoxy-6-({hydroxy[methyl(nitroso)amino]methylidene}amino)-3,5-di-o-methylhexofuranoside
PD162081
AKOS040751115

Research Excerpts

Overview

CGP 6809 is a water-soluble nitrosourea derivative. It is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.

ExcerptReferenceRelevance
"CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer."( CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts.
Fiebig, HH; Löhr, GW; Widmer, KH; Winterhalter, BR, 1989
)
2.44
"CGP 6809 is a water-soluble nitrosourea derivative with quite distinct chemical and biological properties as compared with the well-known representatives of this class of compounds. "( CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties.
Kanter, PM; Matter, A; Müller, M; Schieweck, K; Schmidt-Ruppin, KH; Stanek, J, 1989
)
3.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]